Download PDF
Seminars in Neurosurgery 2001; 12(3): 333-336
DOI: 10.1055/s-2001-33624
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Treatment of Recurrent Nonfunctioning Pituitary Adenomas

Ivan Ciric
  • Division of Neurosurgery, Northwestern University Medical School, Evanston, Illinois
Further Information

Publication History

Publication Date:
27 August 2002 (online)

    Permissions and Reprints

ABSTRACT

The term nonfunctioning pituitary adenomas is probably a misnomer because we tend to group into this category pituitary tumors that do not secrete prolactin, growth hormone, or adrenocorticotropic hormone. In fact, many of these so-called nonfunctioning pituitary adenomas do secrete different hormones, most frequently the alpha subunit of the follicle-stimulating hormone. Their behavior and natural course, however, parallel that of the truly nonfunctioning pituitary adenomas. Considering this, and the fact that there is no effective medical management for these tumors, they will be included in our discussion of the treatment of recurrent nonfunctioning pituitary adenomas in this article.

KEYWORDS

Residual - recurrent - pituitary - adenoma - diagnosis - treatment

REFERENCES

  • 1 Losa M, Mangili F, Terreni M R. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.  Neurosurg . 2000;  47 1313-1319
    PubMedGoogle Scholar
  • 2 Chae Y S, Flotte T, Hsu D W, Preffer F, Hedley-Whyte E T. Flow cytometric DNA ploidy and cells phase fractions in recurrent human pituitary adenomas: a correlative study of flow cytometric analysis and the expression of proliferating cell nuclear antigen.  Gen Diag Pathol . 1996;  142 89-95
    PubMedGoogle Scholar
  • 3 Mindermann T, Kovacs K, Wilson C B. Changes in the immunophenotype of recurrent pituitary adenomas.  Neurosurg . 1994;  35 39-44
    PubMedGoogle Scholar
  • 4 Clayton R N, Pfeifer M, Atkinson A B. Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins.  Clin Cancer Res . 2000;  6 3973-3982
    PubMedGoogle Scholar
  • 5 Metzger A K, Mohapatra G, Minn Y A. Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization.  J Neurosurg . 1999;  90 306-314
    PubMedGoogle Scholar
  • 6 Ciric I, Mikhael M, Stafford T, Lawson L, Garces R. Transsphenoidal microsurgery of pituitary macroadenoma with long-term follow-up results.  J Neurosurg . 1983;  59 395-401
    CrossrefPubMedGoogle Scholar
  • 7 Lillehei K O, Kirschman D L, Kleinschmidt-De Masters K B, Ridgway E C. Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas.  Neurosurg . 1998;  43 432-439
    PubMedGoogle Scholar
      >